StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

Equities researchers at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note issued on Thursday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Down 1.3 %

NYSE OGEN opened at $0.28 on Thursday. Oragenics has a 52 week low of $0.25 and a 52 week high of $5.27. The firm has a market capitalization of $3.47 million, a price-to-earnings ratio of -0.04 and a beta of 0.40. The company has a fifty day moving average of $0.33 and a two-hundred day moving average of $0.59.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.